Embedded Files
THE RELATION BETWEEN MRI CHANGES, CALCITONIN GENE-RELATED PEPTIDE AND BLOOD LIPID IN MIGRAINE PATIENTS
THE RELATION BETWEEN MRI CHANGES, CALCITONIN GENE-RELATED PEPTIDE AND BLOOD LIPID IN MIGRAINE PATIENTS
Anmar Ahmed Ali a, Nazaneen Akbar Omer b, Zana A. Mohammed c, and Sarwer Jamal Al-Bajalan c
a Department of Neurology, Shar Teaching Hospital, Sulaimani, Iraq.
b Department of Medical Biochemistry, College of Medicine, University of Sulaimani, Sulaimani, Iraq.
c Department of Medicine, College of Medicine, University of Sulaimani, Sulaimani, Iraq.
Submitted: 10/10/2020; Accepted: 20/4/2021; Published: 21/9/2021
DOI Link: https://doi.org/10.17656/jsmc.10310
ABSTRACT
Background
Vascular-neuronal systems are highly affected by lipid levels, and migraine, associated with calcitonin gene-related peptide (CGRP) changes. Therefore, magnetic resonance imaging (MRI) has recently been employed to evaluate headaches in patients with migraines.
Objectives
This study investigates the relationship between MRI changes and blood lipid and CGRP levels in migraineurs
Materials and Methods
This case-control study was carried out on 93 patients with migraines and 30 healthy individuals in Shar Teaching Hospital from Oct. 2018 to Oct. 2019. Detailed history and clinical examination were conducted for all of the participants. Data including weight, height, body mass index (BMI), fasting blood glucose (FBG), lipid profile, and CGRP levels were collected. In addition, MRI was performed for all of the participants.
Results
The mean age of the patients was 33 years; 86% of them were females. Brain MRI lesions were detected in 22 (23.7%) of the patients vs 2 (6.7%) of the controls with significant differences (p=0.04). The lesions were observed on fluid-attenuated inversion recovery (FLAIR) in 21 (22.6%) or T2 in 6(6.5%). No lesions were detected on T1 or diffusion-weighted images (DWI). There were no significant relationships between the MRI findings and the CGRP, lipid profile, FBG, or vitamin-D3 levels of the patients (p>0.05). Moreover, the patients and controls were comparable in their lipid profile, FBG, vitamin-D3, or CGRP levels (p>0.05).
Conclusion
Although MRI lesions were detected in a significant proportion of migraine patients, these findings were not significantly related to changes in CGRP and lipid profile levels.
KEYWORDS
Migraine, Lipid profile, Calcitonin gene-related peptide (CGRP).
References
1. Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for treating acute migraine attacks: Results from a phase II study. Cephalalgia [Internet]. 2011 May 20 [cited 2020 Sep 28];31(5):573–84.
2. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543–59.
3. Park L, Uekawa K, Garcia-Bonilla L, Koizumi K, Murphy M, Pistik R, et al. Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer Aβ Peptides. Circ Res. 2017;121(3):258–69.
4. Del Zotto E, Pezzini A, Giossi A, Volonghi I, Padovani A. Migraine and ischemic stroke: A debated question. Vol. 28, Journal of Cerebral Blood Flow and Metabolism. 2008. p. 1399–421.
5. Bousser MG, Welch KMA. Relation between migraine and stroke. Vol. 4, Lancet Neurology. 2005. p. 533–42.
6. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. Vol. 330, British Medical Journal. 2005. p. 63–5.
7. Lipton RB, Bigal ME. The epidemiology of migraine. Vol. 118 Suppl, The American journal of medicine. Excerpta Medica; 2005. p. 3–10.
8. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: Systematic review and meta-analysis. BMJ. 2009;339(7728):1015.
9. Kurth T, Mohamed S, Maillard P, Zhu YC, Chabriat H, Mazoyer B, et al. Headache, migraine, and structural brain lesions and function: Population-based epidemiology of vascular ageing-MRI study. BMJ [Internet]. 2011 Jan 22 [cited 2020 Jun 1];342(7790):215.
10. Hamed SA, Hamed EA, Ezz Eldin AM, Mahmoud NM. Vascular Risk Factors, Endothelial Function, and Carotid Thickness in Patients with Migraine: Relationship to Atherosclerosis. J Stroke Cerebrovasc Dis. 2010 March 1;19(2):92–103.
11. Tietjen GE, Herbal NA, White L, Utley C, Kosmyna JM, Khuder SA. Migraine and biomarkers of endothelial activation in young women. Stroke. 2009;40(9):2977–82.
12. Gruber HJ, Bernecker C, Pailer S, Lechner A, Horejsi R, Möller R, et al. Lipid profile in normal weight migraineurs - Evidence for cardiovascular risk. Eur J Neurol. 2010;17(3):419–25.
13. Monastero R, Pipia C, Cefalù AB, Liver ET, Rosano R, Camarda R, et al. association between plasma lipid levels and migraine in subjects aged ≥50 years: Preliminary data from the Zabùt Aging Project. Neurol Sci [Internet]. 2008 May 11 [cited 2020 Sep 28];29(SUPPL. 1):179–81.
14. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk: A systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.
15. Gruber HJ, Bernecker C, Pailer S, Fauler G, Horejsi R, Möller R, et al. Hyperinsulinaemia in migraineurs is associated with nitric oxide stress. Cephalalgia [Internet]. 2010 May 1 [cited 2020 Sep 28];30(5):593–8.
16. Tsushima Y, Endo K. MR imaging in the evaluation of chronic or recurrent headache. Radiology. 2005;235(2):575–9.
17. Dent W, Spiss HK, Helbok R, Matuja WBP, Scheunemann S, Schmutzhard E. Prevalence of migraine in a rural area in South Tanzania: A door-to-door survey. Vol. 24, Cephalalgia. 2004. p. 960–6.
18. Olesen J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia [Internet]. 2018 Jan 25 [cited 2020 May 28];38(1):1–211.
19. Wolters PL, Martin S, Merker VL, Gardner KL, Hingtgen CM, Tonsgard JH, et al. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. [Internet]. Vol. 81, Neurology. Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology; 2013 [cited 2020 September 11]. p. S6–14.
20. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical Utility of an Instrument Assessing Migraine Disability: The Migraine Disability Assessment (MIDAS) Questionnaire. Headache J Head Face Pain [Internet]. 2001 Oct 4 [cited 2020 Oct 2];41(9):854–61.
21. Ng CD. Stratification of BMI categories among older adults within and across countries. Public Health Nutr [Internet]. 2020 February 1 [cited 2020 July 4];23(2):254–63.
22. Cheng B, Ebinger M, Kufner A, Köhrmann M, Wu O, Kang DW, et al. Hyperintense vessels on acute stroke fluid-attenuated inversion recovery imaging: Associations with clinical and other MRI findings. Stroke [Internet]. 2012 Nov [cited 2020 Sep 28];43(11):2957–61.
23. Kobayashi J, Uehara T, Toyoda K, Endo K, Ohara T, Fujinami J, et al. Clinical significance of fluid-attenuated inversion recovery vascular hyperintensities in the transient ischemic attack. Stroke. 2013;44(6):1635–40.
24. Dinia L, Bonzano L, Albano B, Finocchi C, Del Sette M, Saitta L, et al. White Matter Lesions Progression in Migraine with Aura: A Clinical and MRI Longitudinal Study. J Neuroimaging [Internet]. 2013 Jan 1 [cited 2020 Oct 9];23(1):47–52.
25. Paemeleire K. Brain lesions and cerebral functional impairment in migraine patients. J Neurol Sci. 2009 August 15;283(1–2):134–6.
26. Kamson DO, Illés Z, Aradi M, Orsi G, Perlaki G, Leél-Ssy E, et al. Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis. J Clin Neurosci. 2012 May 1;19(5):696–701.
27. Kamson DO, Illés Z, Aradi M, Orsi G, Perlaki G, Leél-Ssy E, et al. Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis. J Clin Neurosci. 2012 May 1;19(5):696–701.
28. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Vol. 84, Physiological Reviews. 2004. p. 903–34.
29. Buxton RB. Dynamic models of BOLD contrast. Vol. 62, NeuroImage. 2012. p. 953–61.
30. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72(2):234–40.
31. Nowaczewska M, Wiciński M, Osiński S, Kázmierczak H. The role of vitamin D in primary headache–from potential mechanism to treatment. Nutrients. 2020;12(1).
32. Martínez-Lapiscina EH, Mahatanan R, Lee CH, Charoenpong P, Hong JP. A systematic review and meta-analysis of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis. J Neurol Sci. 2020 April 15; 411,116668.
33. Sinha S, Misra A, Kumar V, Jagannathan NR, Bal CS, Pandey RM, et al. Proton magnetic resonance spectroscopy and single-photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clin Endocrinol (Oxf). 2004;61(2):182–9.
34. Choi HJ, Byun MS, Yi D, Choe YM, Sohn BK, Baek HW, et al. Association Between Serum Triglycerides and Cerebral Amyloidosis in Cognitively Normal Elderly. Am J Geriatr Psychiatry. 2016;24(8):604–12.
35. Gottesman RF, Schneider ALC, Zhou Y, Coresh J, Green E, Gupta N, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA - J Am Med Assoc. 2017;317(14):1443–50.
36. Vemuri P, Knopman DS, Lesnick TG, Przybelski SA, Mielke MM, Graff-Radford J, et al. Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals. JAMA Neurol. 2017;74(6):718–26.
37. Giubilei F, Antonini G, Di Legge S, Sormani MP, Pantano P, Antonini R, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand. 2002;106(2):109–12.
38. Janoska M, Chorążka K, Domitrz I. Migraine frequency and its association with dyslipidemia in women. Neurol Neurochir Pol. 2015;49(2):95–8.
39. Kurth T, Ridker PM, Buring JE. Migraine and biomarkers of cardiovascular disease in women. Cephalalgia. 2008;28(1):49–56.
40. Mortimer JA, Borenstein AR, Ding D, Decarli C, Zhao Q, Copenhaver C, et al. High average fasting blood glucose is associated with dementia in Chinese elderly. Alzheimer's Dement. 2010;6(6):440–7.
41. Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006;46(SUPPL. 1): S3–8.
42. Moskowitz MA. Pathophysiology of Headache?Past and Present. Headache J Head Face Pain [Internet]. 2007 Apr [cited 2020 Sep 29];47(s1):S58–63.
43. Fan PC, Kuo PH, Chang SH, Lee WT, Wu RM, Chiou LC. Plasma calcitonin gene-related peptide in diagnosing and predicting pediatric migraine. Cephalalgia. 2009;29(8):883–90.
44. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.
45. Young NP, Elrashidi MY, McKie PM, Ebbert JO. Neuroimaging utilization and findings in headache outpatients: Significance of red and yellow flags. Cephalalgia. 2018;38(12):1841–8.
46. Wang R, Liu R, Dong Z, Su H, Ao R, Liu Y, et al. Unnecessary Neuroimaging for Patients With Primary Headaches. Headache. 2019;59(1):63–8.
47. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–76.
© The Authors, published by University of Sulaimani, College of Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Page updated
Report abuse